How about MPH.TO

Green888 · Sep 14th, 2005, 22:16

RT

gorilla_ch · Sep 15th, 2005, 09:54

一般，现在在高位。感觉mm在用利好消息出以前的货获利。

Green888 · Sep 21st, 2005, 14:27

It's next CLL.TO ???

We will see ....

Green888 · Dec 8th, 2005, 14:20

Had nice run....

Parntership will be announced within 6 months .

If you are interesting , pls check FA ..

I am still holding until....

Green888 · Mar 13th, 2006, 17:07

Today close @2.17

Event on Calendar:

1. POD90 results will be out on April
2. Partner will be announced this summer
3. MC-1 will start Phase III after Partner announced .
4. MPH has good product pipelines
5. Insiders huge bot around @1. when I first commended here
6. So far , no similar drug on market or on the trail.

The stock OS is 79.9M, you can do your own math for Share price if we can reach what CEO said on ROBTV .

Good luck all.

Last week MPH CEO ROBTV interview link:
http://www.robtv.com/servlet/HTMLTemplate/!robVideo/robtv0726.20060308.00037000-00037624-clip1/h/220asf///

Green888 · Mar 14th, 2006, 11:32

+0.13 ,2.30now

Green888 · Mar 14th, 2006, 16:56

Copied from MPH forum :

MPH Info/ Due Diligence........
* MPH's cash and cash equivalents... $13,756,000 at January 4, 2006.
* Their Burn Rate is on average $2.5 mil Cdn or $2.1 mil US/qtr.
* Phase 2 and Phase 3 trials are being designed in very close consultation with the FDA to ensure the strictest guidelines are adhered to.
* MPH Currently holds 15 Patents and 17 more are pending.
* MPH was granted "Fast Track Status" on Sept.5/05 for it's Cardioprotective Lead Drug MC-1.
* MPH is using a unique intravenous MC-1 formulation in it's Ph2 and Ph3 trials as necessary for the most acute cases to administer the drug in the fastest means possible to ensure the quickest absorbtion rate by the body.
MC-1 is being tested for it's affects on:
~CABG - Coronary Artery Bypass Graft Surgery
~ACS - Acute Coronary Syndrome
~AMI - Acute Myocardial Infarction (heart attacks)
~Stroke as well as Angioplasty

MC-4232 is being tested for it's affects on:
~Hypertension - (Abnormally High Blood Pressure)
~Diabetes

MC-4262 is being tested for it's affects on Metabolic Syndrom.

MC-45308 is being tested for it's affects on Thrombosis (Clots in blood vessels).

MC-5422 is being tested for it's affects on Ischemic Reperfusion.

****MPH's drug Candidate MC-45308 in preclinical research is considered a Breakthough in preventing blood clots as it has demonstrated both Anti-platelet and Anti-coagulant effects...

Dr Friesen stated "A drug of this nature currently is non existent within the Antithrombotic marketplace!"

****Sept.14/05 MPH announced positive Ph2 results for their drug MC-4232 in a matched study with MC-1 and the Ace Inhibitor Lisinopril in the treatment of patients with coexisting diabetes and hypertension, and demonstrated it was safe and well tolerated at all dose levels.

Dr Friesen stated "The Matched trial has exceeded our expectations, demonstrating the outstanding clinical benefits of MC-4232!"

****Dec.5/05 MPH announced positive Ph2 results for MC-1 in the MEND-CABG Trial with amazing results such as the 46.9% reduction in non fatal Myocardial Infarction.

Dr. Friesen stated "The strong efficacy signal observed with MC-1 in MEND-CABG, highlighted by the statistically significant reduction in heart attacks, have exceeded our own expectations, and clearly warrants advancing MC-1 into Pivotol Ph3 developement.

They're expecting a TON of news in a very short period of time. By the end of Summer we will have announcements on all of the following:

1) MC-1 Phase3 begins for MEND-CABG and Matched studies for ACS.
2) MC-4232 Phase3 begins.
3) MC-4262 Phase2 begins.
4) MC-45308 Phase1 begins.
5) MC-5422 Pre-Clinical Trials begin.
6) Results of Phase2, MC-1 MEND-CABG, Post Operative 90 day data.
7) Partnership agreement for the Phase3 trials with a Large Pharma.

It's absolutely incredible how everything is coming together at the same time, and most investors are thinking of only one or two potential news releases. Geeeesh. When this thing blows, it'll blow the top off the Biotech Sector Lid. There's just so much on the plate here I can't comprehend how Dr.Friesen and the management team keep it all organized. If there's delays, I understand why. Keep in mind as well that these potential announcements don't even include the rest of the "Behind the Scenes" stuff such as other R&D, Running the day to day business, obtaining new Board members, upcoming Patents not yet recieved but applied for, Biotec Conferences etc....

We're sitting on a Powder Keg and the fuse is lit!!

Medicure has a Great Website...... http://www.medicure.com/

Cheers..... Dead

You can view my charts at the link below......

http://stockcharts.com/def/servlet/F...t?obj=ID871828

Green888 · Apr 13th, 2006, 11:02

Very positive news out yesterday , this is my core holding and plan to hold 2 more years.

******************************
Press Release Source: Medicure Inc.

Medicure Reports on MEND-CABG End of Phase II Meeting With the FDA
Wednesday April 12, 8:00 am ET

WINNIPEG, MANITOBA--(MARKET WIRE)--Apr 12, 2006 -- Medicure Inc. (Toronto:MPH.TO - News)(AMEX:MCU - News), a cardiovascular drug discovery and development company, today announced that based on the positive Phase II MEND-CABG study and a recent End of Phase II meeting with the U.S. Food and Drug Administration (FDA), the Company plans to proceed with a single confirmatory Phase III study to gain approval for MC-1 in the reduction of cardiovascular events in patients undergoing coronary artery bypass graft (CABG) surgery. MC-1 has received a Fast Track designation from the FDA.
ADVERTISEMENT

Based on the End of Phase II meeting, Medicure plans to use a composite of cardiovascular death and non-fatal myocardial infarction (primary definition peak CK-MB greater than or equal to 100ng/ml) at post operative day (POD) 30 as the primary endpoint for the Phase III study. Initiation of this study is targeted for the second half of calendar 2006.

"We are extremely pleased with the outcome of the End of Phase II meeting with the FDA. A single confirmatory study provides Medicure the most efficient and affordable path for MC-1's Phase III development, and is a valuable asset in our partnership negotiations," commented Medicure's President and CEO, Albert D. Friesen, PhD. "MC-1 has the opportunity to be the first product indicated to reduce cardiovascular events associated with ischemia and/or ischemic reperfusion injury in CABG patients, targeting a significant unmet medical need. We look forward to working with the FDA in expediting the development of MC-1."

MC-1 is a small molecule that reduces the amount of damage to the heart following ischemia and/or ischemic reperfusion injury. Studies with MC-1 suggest that it does this by protecting cardiomyocytes (heart muscle cells). Since cardiomyocytes are essential for normal heart function and do not regenerate themselves following an ischemic event, their preservation is key to minimizing ischemic damage and maintaining proper heart function. MC-1's cardioprotective properties have been demonstrated in the Phase II MEND-1 study in patients undergoing percutaneous coronary interventions and the Phase II MEND-CABG study in patients undergoing CABG surgery.

About Medicure Inc.

Medicure Inc. is a cardiovascular drug discovery and development company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine, the largest pharmaceutical market sector. The Company's solid position in this field is supported by the following attributes:

- Cardiovascular focused pipeline: a global market of over US $70 billion

- Two drugs - MC-1 & MC-4232 - in late stage clinical development

- Four positive Phase II trials completed

- FDA Fast Track designation for MC-1

- Unique products addressing major, inadequately served markets

- Dual action antithrombotic, MC-45308, with positive preclinical results

Medicure also has a medicinal chemistry based Drug Discovery program focused on discovery and advancement of novel small molecule anti-ischemics and antithrombotics towards human clinical studies.

This press release contains forward-looking statements that involve risks, which may cause actual results to differ materially from the statements made, and accordingly may be deemed to be forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Sep 14th, 2005, 22:16	#1
Green888 Senior Member 注册日期: Sep 2005 帖子: 766	How about MPH.TO RT
Green888 Senior Member 注册日期: Sep 2005 帖子: 766

Sep 15th, 2005, 09:54	只看该作者 #2
gorilla_ch Senior Member 注册日期: Jul 2004 帖子: 112 声望: 0	一般，现在在高位。感觉mm在用利好消息出以前的货获利。
gorilla_ch Senior Member 注册日期: Jul 2004 帖子: 112 声望: 0

Sep 21st, 2005, 14:27	只看该作者 #3
Green888 Senior Member 注册日期: Sep 2005 帖子: 766 声望: 253766	It's next CLL.TO ??? We will see ....

Dec 8th, 2005, 14:20	只看该作者 #4
Green888 Senior Member 注册日期: Sep 2005 帖子: 766 声望: 253766	Had nice run.... Parntership will be announced within 6 months . If you are interesting , pls check FA .. I am still holding until....

Mar 13th, 2006, 17:07	只看该作者 #5
Green888 Senior Member 注册日期: Sep 2005 帖子: 766 声望: 253766	Today close @2.17 Event on Calendar: 1. POD90 results will be out on April 2. Partner will be announced this summer 3. MC-1 will start Phase III after Partner announced . 4. MPH has good product pipelines 5. Insiders huge bot around @1. when I first commended here 6. So far , no similar drug on market or on the trail. The stock OS is 79.9M, you can do your own math for Share price if we can reach what CEO said on ROBTV . Good luck all. Last week MPH CEO ROBTV interview link: http://www.robtv.com/servlet/HTMLTemplate/!robVideo/robtv0726.20060308.00037000-00037624-clip1/h/220asf///

Mar 14th, 2006, 11:32	只看该作者 #6
Green888 Senior Member 注册日期: Sep 2005 帖子: 766 声望: 253766	+0.13 ,2.30now

Mar 14th, 2006, 16:56	只看该作者 #7
Green888 Senior Member 注册日期: Sep 2005 帖子: 766 声望: 253766	Copied from MPH forum : MPH Info/ Due Diligence........ * MPH's cash and cash equivalents... $13,756,000 at January 4, 2006. * Their Burn Rate is on average $2.5 mil Cdn or $2.1 mil US/qtr. * Phase 2 and Phase 3 trials are being designed in very close consultation with the FDA to ensure the strictest guidelines are adhered to. * MPH Currently holds 15 Patents and 17 more are pending. * MPH was granted "Fast Track Status" on Sept.5/05 for it's Cardioprotective Lead Drug MC-1. * MPH is using a unique intravenous MC-1 formulation in it's Ph2 and Ph3 trials as necessary for the most acute cases to administer the drug in the fastest means possible to ensure the quickest absorbtion rate by the body. MC-1 is being tested for it's affects on: ~CABG - Coronary Artery Bypass Graft Surgery ~ACS - Acute Coronary Syndrome ~AMI - Acute Myocardial Infarction (heart attacks) ~Stroke as well as Angioplasty MC-4232 is being tested for it's affects on: ~Hypertension - (Abnormally High Blood Pressure) ~Diabetes MC-4262 is being tested for it's affects on Metabolic Syndrom. MC-45308 is being tested for it's affects on Thrombosis (Clots in blood vessels). MC-5422 is being tested for it's affects on Ischemic Reperfusion. **MPH's drug Candidate MC-45308 in preclinical research is considered a Breakthough in preventing blood clots as it has demonstrated both Anti-platelet and Anti-coagulant effects... Dr Friesen stated "A drug of this nature currently is non existent within the Antithrombotic marketplace!" Sept.14/05 MPH announced positive Ph2 results for their drug MC-4232 in a matched study with MC-1 and the Ace Inhibitor Lisinopril in the treatment of patients with coexisting diabetes and hypertension, and demonstrated it was safe and well tolerated at all dose levels. Dr Friesen stated "The Matched trial has exceeded our expectations, demonstrating the outstanding clinical benefits of MC-4232!" **Dec.5/05 MPH announced positive Ph2 results for MC-1 in the MEND-CABG Trial with amazing results such as the 46.9% reduction in non fatal Myocardial Infarction. Dr. Friesen stated "The strong efficacy signal observed with MC-1 in MEND-CABG, highlighted by the statistically significant reduction in heart attacks, have exceeded our own expectations, and clearly warrants advancing MC-1 into Pivotol Ph3 developement. They're expecting a TON of news in a very short period of time. By the end of Summer we will have announcements on all of the following: 1) MC-1 Phase3 begins for MEND-CABG and Matched studies for ACS. 2) MC-4232 Phase3 begins. 3) MC-4262 Phase2 begins. 4) MC-45308 Phase1 begins. 5) MC-5422 Pre-Clinical Trials begin. 6) Results of Phase2, MC-1 MEND-CABG, Post Operative 90 day data. 7) Partnership agreement for the Phase3 trials with a Large Pharma. It's absolutely incredible how everything is coming together at the same time, and most investors are thinking of only one or two potential news releases. Geeeesh. When this thing blows, it'll blow the top off the Biotech Sector Lid. There's just so much on the plate here I can't comprehend how Dr.Friesen and the management team keep it all organized. If there's delays, I understand why. Keep in mind as well that these potential announcements don't even include the rest of the "Behind the Scenes" stuff such as other R&D, Running the day to day business, obtaining new Board members, upcoming Patents not yet recieved but applied for, Biotec Conferences etc.... We're sitting on a Powder Keg and the fuse is lit!! Medicure has a Great Website...... http://www.medicure.com/ Cheers..... Dead You can view my charts at the link below...... http://stockcharts.com/def/servlet/F...t?obj=ID871828

Apr 13th, 2006, 11:02	只看该作者 #8
Green888 Senior Member 注册日期: Sep 2005 帖子: 766 声望: 253766	Very positive news out yesterday , this is my core holding and plan to hold 2 more years. ****************************** Press Release Source: Medicure Inc. Medicure Reports on MEND-CABG End of Phase II Meeting With the FDA Wednesday April 12, 8:00 am ET WINNIPEG, MANITOBA--(MARKET WIRE)--Apr 12, 2006 -- Medicure Inc. (Toronto:MPH.TO - News)(AMEX:MCU - News), a cardiovascular drug discovery and development company, today announced that based on the positive Phase II MEND-CABG study and a recent End of Phase II meeting with the U.S. Food and Drug Administration (FDA), the Company plans to proceed with a single confirmatory Phase III study to gain approval for MC-1 in the reduction of cardiovascular events in patients undergoing coronary artery bypass graft (CABG) surgery. MC-1 has received a Fast Track designation from the FDA. ADVERTISEMENT Based on the End of Phase II meeting, Medicure plans to use a composite of cardiovascular death and non-fatal myocardial infarction (primary definition peak CK-MB greater than or equal to 100ng/ml) at post operative day (POD) 30 as the primary endpoint for the Phase III study. Initiation of this study is targeted for the second half of calendar 2006. "We are extremely pleased with the outcome of the End of Phase II meeting with the FDA. A single confirmatory study provides Medicure the most efficient and affordable path for MC-1's Phase III development, and is a valuable asset in our partnership negotiations," commented Medicure's President and CEO, Albert D. Friesen, PhD. "MC-1 has the opportunity to be the first product indicated to reduce cardiovascular events associated with ischemia and/or ischemic reperfusion injury in CABG patients, targeting a significant unmet medical need. We look forward to working with the FDA in expediting the development of MC-1." MC-1 is a small molecule that reduces the amount of damage to the heart following ischemia and/or ischemic reperfusion injury. Studies with MC-1 suggest that it does this by protecting cardiomyocytes (heart muscle cells). Since cardiomyocytes are essential for normal heart function and do not regenerate themselves following an ischemic event, their preservation is key to minimizing ischemic damage and maintaining proper heart function. MC-1's cardioprotective properties have been demonstrated in the Phase II MEND-1 study in patients undergoing percutaneous coronary interventions and the Phase II MEND-CABG study in patients undergoing CABG surgery. About Medicure Inc. Medicure Inc. is a cardiovascular drug discovery and development company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine, the largest pharmaceutical market sector. The Company's solid position in this field is supported by the following attributes: - Cardiovascular focused pipeline: a global market of over US $70 billion - Two drugs - MC-1 & MC-4232 - in late stage clinical development - Four positive Phase II trials completed - FDA Fast Track designation for MC-1 - Unique products addressing major, inadequately served markets - Dual action antithrombotic, MC-45308, with positive preclinical results Medicure also has a medicinal chemistry based Drug Discovery program focused on discovery and advancement of novel small molecule anti-ischemics and antithrombotics towards human clinical studies. This press release contains forward-looking statements that involve risks, which may cause actual results to differ materially from the statements made, and accordingly may be deemed to be forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.